Theorem Clinical Research

Leukemia & Lymphoma Society

Louis DeGennaro named president, CEO of Leukemia & Lymphoma Society

Thursday, September 11, 2014 03:33 PM

The Leukemia & Lymphoma Society (LLS) has appointed Louis J. DeGennaro, Ph.D., president and CEO, effective immediately.

More... »


Leukemia & Lymphoma Society awards $12.6 million in research grants

Wednesday, January 8, 2014 01:24 PM

The Leukemia & Lymphoma Society (LLS), a voluntary health agency dedicated to blood cancer, has awarded 21 new grants representing a total investment of $12.6 million to tackle six areas of high unmet medical need in the blood cancers.

More... »


Evotec collaborates with Leukemia & Lymphoma Society

Wednesday, November 6, 2013 12:59 PM

Evotec has entered into an integrated research collaboration with the Leukemia & Lymphoma Society (LLS). Evotec will support one of LLS's Screen-to-Lead Programs (SLP).

More... »

Stemline Therapeutics, Leukemia & Lymphoma Society collaborate

Wednesday, October 30, 2013 11:14 AM

Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.

More... »

LLS, Dana-Farber partner to bring clinical trials to local communities

Friday, June 7, 2013 01:29 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency, joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of blood cancer therapies in community oncology settings across the country.

More... »

LLS, Valor Biotherapeutics partner to advance novel therapy

Thursday, May 30, 2013 04:18 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

More... »

Leukemia & Lymphoma Society expands chief policy, advocacy officer role

Friday, March 8, 2013 10:34 AM

The Leukemia & Lymphoma Society (LLS) has expanded the role of chief policy and advocacy officer Mark Velleca, M.D., Ph.D. Velleca, who has headed LLS' Office of Public Policy in Washington, D.C., since early 2012, will now oversee the newly integrated patient advocacy, policy and programs department.

More... »

Constellation, LLS to develop novel BET inhibitor for hematologic malignancies

Friday, September 21, 2012 01:12 PM

Constellation Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company in the field of epigenetics, has entered into a strategic partnership with the Leukemia & Lymphoma Society (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies.

More... »

Leukemia & Lymphoma Society awards $12M in grants for blood cancer

Thursday, August 30, 2012 11:54 AM

The Leukemia & Lymphoma Society (LLS) of White Plains, N.Y., has awarded 20 grants representing a total investment of $12 million to tackle four areas of high unmet medical need in the blood cancers.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs